ClinicalTrials.gg
Sign In
BiosimilarDrug

HLX02 clinical trials

Also written HLX02.

A product of Trastuzumab; its studies count on that page too.

studies test it
3
open now
0
in phase 3
1
first study started
2015

How each study uses HLX02 has had a first review. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
25 Sept 1998 · HERCEPTIN · BLA 103792 (FDA, Drugs@FDA; as Trastuzumab)
European Union
28 Aug 2000 · Herceptin · EMEA/H/C/000278 (EMA; as Trastuzumab)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

HLX02
3

Studies by the year they started

3 studies that test it; most in 2015 (1)

Studies that test HLX02, by start year
YearStudies
20151
20161
20211

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Breast Neoplasms
1

Who runs them

Industry 3 · Other 0

Shanghai Henlius Biotech (3)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses HLX02 has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Tested on its own · 1 — no other medicine in its arm
Tested with established drugs · 2 — they are given beside it
Start the discussion